US regulators have approved Teva’s Ajovy for the preventative treatment of migraine in adults.
News
AZ to file triple combination therapy for COPD
AstraZeneca has unveiled late-stage data backing use of its triple combination therapy PT010 in patients with chronic obstructive pulmonary disease (COPD).
It’s an industry affair – New Medical & Scientific Excellence Awards attracting entrants by the day
Medical Science Liaison of the Year has been expanded to include three levels of seniority and forms the backbone of the all new Medical and Scientific Excellence Awards, alongside categories for scientific advisors and medical information professionals.
ViiV submits two-drug regimen for HIV in Europe
ViiV Healthcare has submitted an application in Europe for a single-tablet, two-drug regimen of dolutegravir (DTG) and lamivudine (3TC) for the treatment of HIV-1 infection.
NHS summer performance hits new lows
Alarm bells over the NHS’ ability to cope with looming winter pressures are ringing again after some aspects of service performance sunk to new lows in the summer, with record waiting times for A&E and cancer treatment.
Landmark MS trial launches in UK
The biggest ever trial for secondary progressive multiple sclerosis (SPMS) has kicked off in the UK at around 30 sites in England, Scotland, Wales, Northern Ireland and Eire.
US approves AZ’ hairy cell leukaemia drug
AstraZeneca and its biologics R&D arm MedImmune have bagged US approval of Lumoxiti for the treatment of hairy cell leukaemia (HCL), marking the first new treatment option in 20 years.
Boehringer buys ViraTherapeutics
Boehringer Ingelheim has exercised an option to acquire all shares of oncolytic virus company ViraTherapeutics.
A&E attendances in England leap 22% in a decade
The number of people visiting A&E in England has jumped by more than one-fifth in ten years, official figures show.
Gilead, Precision to co-develop hepatitis B therapies
Gilead and Precision BioSciences are to work together on developing gene-editing treatments against hepatitis B.
DH moves to ensure equal access to cancer drugs in NI
The Department of Health in Northern Ireland has unveiled plans to boost access to innovative new medicines for cancers and other conditions.
PharmaTimes Marketer of the Year competition – last chance to enter!
Entry to the 2018 PharmaTimes Marketer of the Year competition will close on Friday 14 September.
Showcase your agency’s abilitity to deal with real life challenges
The highly prestigious PharmaTimes Communications Team of the Year competition will close for entry at midnight on Friday. Take this opportunity to compete alongside other healthcare agencies in a one-off challenge to shape real-life solutions for one of the UK’s leading charities.
Gilead, Galapagos’ filgotinib hits goals in RA trial
Gilead and Galapagos have unveiled another set of promising data for JAK inhibitor filgotinib, this time in rheumatoid arthritis.
MSD to file antibiotic Zerbaxa for pneumonia
MSD is gearing up to file antibiotic Zerbaxa on both sides of the Atlantic for certain forms of pneumonia on the success of a late-stage trial backing its safety and efficacy.
